治疗多重耐药铜绿假单胞菌感染的临床探究

目的:探索治疗多重耐药铜绿假单胞菌感染的方法。方法:85例多重耐药铜绿假单胞菌呼吸道感染患者随机分为试验组与对照组。试验组给予磷霉素4g+5%葡萄糖注射液100mL静脉滴注完毕后60min立即给予头孢哌酮/舒巴坦4g+0.9%氯化钠注射液250mL静脉滴注,2次.d-1。对照组采用头孢哌酮/舒巴坦4g+0.9%氯化钠注射液250mL静脉滴注,2次.d-1,联合阿米卡星80mg+5%葡萄糖注射液250mL静脉滴注,1次.d-1。2组疗程均为14d。结果:试验组总有效率为93.02%,疗效优于对照组的42.86%(χ2=24.826,P=0.000)。结论:磷霉素+头孢哌酮/舒巴坦为治疗多重耐药铜绿假单胞菌感染的新途径。

Management of Multidrug Resistant Pseudomonas Aeruginosa-induced Infection

OBJECTIVE: To explore the therapy for multidrug resistant pseudomonas aeruginosa- induced infection. MET-HODS: A total of 85 patients infected with multidrug resistant pseudomonas aeruginosa were randomized to trial group and control group: the trial group was infused bid with Fosfomycin 4g+ 5% GS 100mL followed by the infusion of Cefperazone/immediatelySulbactam 4g+ 0. 9% NS 250mL with 60min interval; the control group was infused with Cefperazone/Sulbactam 4g+ 0. 9% NS 250mL bid and Amikacin 80mg+ 5% GS 250mL qd. The course of treatment for both groups was 14d. RESULTS: The trial group was superior to control group in efficacy( 93. 02% vs. 42. 86% in total effective rates, χ 2=24. 826, P=0. 000) . CON-CLUSION: Fosfomycin+ Cefperazone/Sulbactam can be adopted as a new therapy in the management of multidrug resistant pseudomonas aeruginosa- induced infection.